EcoDrugPlus

Phospholipase A2, Membrane Associated

Ensembl ID : ENSBMUG00000022494
Gene Symbol: LOC102276213
2 Cross references
145 Possible Orthologues:

Phospholipase A2, Membrane Associated

Ensembl ID : ENSBMUG00000022460
Gene Symbol: LOC102275927
2 Cross references
145 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSBMUG00000008528
Gene Symbol: GART
3 Cross references
247 Possible Orthologues:

Plasminogen

Ensembl ID : ENSBMUG00000003160
Gene Symbol: PLG
2 Cross references
269 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSBMUG00000001492
Gene Symbol: PLAT
3 Cross references
203 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSBMUG00000017560
Gene Symbol: PTAFR
3 Cross references
224 Possible Orthologues:

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSBMUG00000015377
Gene Symbol: PDGFRA
3 Cross references
204 Possible Orthologues:

Platelet Derived Growth Factor Receptor Beta

Ensembl ID : ENSBMUG00000012182
Gene Symbol: PDGFRB
3 Cross references
247 Possible Orthologues:

Platelet Derived Growth Factor Subunit B

Ensembl ID : ENSBMUG00000000434
Gene Symbol: PDGFB
3 Cross references
263 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSBMUG00000022705
Gene Symbol: PLK1
3 Cross references
188 Possible Orthologues:

Polo Like Kinase 4

Ensembl ID : ENSBMUG00000022590
Gene Symbol: PLK4
3 Cross references
215 Possible Orthologues:

Poly [Adp-Ribose] Polymerase 1

Ensembl ID : ENSBMUG00000014506
Gene Symbol: LOC102272990
2 Cross references
198 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).